IDEAS home Printed from https://ideas.repec.org/p/ohe/monogr/000456.html
   My bibliography  Save this paper

Updating the Cost of a New Chemical Entity

Author

Listed:
  • Hannah Kettler

Abstract

The objective of this paper is to analyse the existing estimates of NCE costs and look at the subsequent changes in cost components and at the impact of structural change in the R&D process. These discussions cannot substitute for new estimates that are based on more recent company data but, in the absence of such new estimates, they do provide some indication of the direction and magnitude of likely cost changes that have occurred in the 1980s and 1990s.

Suggested Citation

  • Hannah Kettler, 1999. "Updating the Cost of a New Chemical Entity," Monograph 000456, Office of Health Economics.
    • Handle: RePEc:ohe:monogr:000456
    as

    Download full text from publisher

    File URL: https://www.ohe.org/publications/updating-cost-new-chemical-entity/attachment-259-1999_updating_the_cost_nce_kettler/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Helen Simpson, 1998. "Biotechnology and the Economics of Discovery in the Pharmaceutical Industry," Monograph 000432, Office of Health Economics.
    2. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
    3. Uwe Reinhardt, 1998. "Accountable Health Care: Is it compatible with social solidarity?," Monograph 000431, Office of Health Economics.
    4. Adrian Towse, 1995. "Industrial Policy and the Pharmaceutical Industry," Monograph 000414, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Anne Mills, 2002. "La science et la technologie en tant que biens publics mondiaux : S'attaquer aux maladies prioritaires des pays pauvres," Revue d’économie du développement, De Boeck Université, vol. 10(1), pages 117-139.
    2. Hannah Kettler, 2001. "Consolidation and Competition in the Pharmaceutical Industry," Monograph 000468, Office of Health Economics.
    3. Hannah Kettler, 2000. "Narrowing the Gap between provision and need for medicines in developing countries," Monograph 000461, Office of Health Economics.
    4. Steven Casper;Hannah Kettler, 2000. "The Road to Sustainability in the UK and German Biotechnology Industries," Monograph 000466, Office of Health Economics.
    5. Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Office of Health Economics, 1998. "Controlling NHS Expenditure: The Impact of Labour’s NHS White Papers," Monograph 000435, Office of Health Economics.
    2. Hannah Kettler, 1998. "Competition through Innovation, Innovation through Competition," Monograph 000434, Office of Health Economics.
    3. Yu-Shan Chen & Ke-Chiun Chang, 2009. "Using neural network to analyze the influence of the patent performance upon the market value of the US pharmaceutical companies," Scientometrics, Springer;Akadémiai Kiadó, vol. 80(3), pages 637-655, September.
    4. Thomas Ã…stebro, 1998. "Basic Statistics on the Success Rate and Profits for Independent Inventors," Entrepreneurship Theory and Practice, , vol. 23(2), pages 41-48, December.
    5. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    6. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
    7. Yu-Shan Chen & Ke-Chiun Chang, 2010. "The nonlinear nature of the relationships between the patent traits and corporate performance," Scientometrics, Springer;Akadémiai Kiadó, vol. 82(1), pages 201-210, January.
    8. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    9. Larkin, Yelena & Lyandres, Evgeny, 2019. "Inefficient mergers," Journal of Banking & Finance, Elsevier, vol. 108(C).
    10. Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
    11. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    12. Ryan, Michael P., 2010. "Patent Incentives, Technology Markets, and Public-Private Bio-Medical Innovation Networks in Brazil," World Development, Elsevier, vol. 38(8), pages 1082-1093, August.
    13. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    14. Liu, Xiaohui & Xia, Tianjiao & Jiangyong, Lu & Lin, Daomi, 2019. "Under what institutional conditions does overseas business knowledge contribute to firm performance?," International Business Review, Elsevier, vol. 28(3), pages 588-602.
    15. Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
    16. Patricia M. Danzon & Allison Percy, 1999. "The Effects of Price Regulation on Productivity in Pharmaceuticals," NBER Chapters, in: International and Interarea Comparisons of Income, Output, and Prices, pages 371-418, National Bureau of Economic Research, Inc.
    17. Lee, Daeyong, 2018. "Impact of the excise tax on firm R&D and performance in the medical device industry: Evidence from the Affordable Care Act," Research Policy, Elsevier, vol. 47(5), pages 854-871.
    18. Richard T. Thakor & Andrew W. Lo, 2015. "Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry," NBER Working Papers 20903, National Bureau of Economic Research, Inc.
    19. Anna Nagurney & Dong Li, 2015. "A supply chain network game theory model with product differentiation, outsourcing of production and distribution, and quality and price competition," Annals of Operations Research, Springer, vol. 226(1), pages 479-503, March.
    20. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.

    More about this item

    Keywords

    Updating the Cost of a New Chemical Entity;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:monogr:000456. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.